Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death

Inclusion criteria : * Implantable Cardioverter Defibrillator (ICD) patients with a Left Ventricular Ejection Fraction (LVEF) of 40% or less AND one of the following criteria: * at least one ICD therapy for Ventricular Tachycardia (VT) OR * Ventricular Fibrillation (VF) in the previous month OR * ICD implantation in the previous month for documented VT/VF Exclusion criteria : * Patients of either sex aged below 21 years (or the age of legal consent of the country), * Women of childbearing potential without adequate birth control or pregnant or breastfeeding women * Patients with known ICD lead problem (lead dislodgement) * ICD without the following characteristics : * data logging function with cumulative counting of device intervention (shocks and anti-tachycardia pacing \[ATP\]) * electrogram storage capabilities * ventricular demand pacing. * Recent unstable angina pectoris or myocardial infarction (\< 4 weeks), * History of torsades de pointes, * Genetic channelopathies including congenital long QT syndrome, * Wolff-Parkinson-White syndrome, * Patients in unstable hemodynamic condition such as acute pulmonary edema within 12 hours prior to start of study medication; cardiogenic shock; treatment with intravenous pressor agents; patients on respirator; congestive heart failure of stage New York Heart Association (NYHA) IV within the last 4 weeks; uncorrected, hemodynamically significant primary obstructive valvular disease; hemodynamically significant obstructive cardiomyopathy; a cardiac operation or revascularization procedure within 4 weeks preceding randomization, * Incessant sustained VT/VF (VT/VF that recurs promptly despite termination attempts) during the three days preceding randomization. * Patients with inappropriate (not triggered by VT nor VF) shocks during the month preceding randomization. * Clinically relevant haematologic, hepatobiliary (ALT, AST \> 3 times the upper limit of normal at randomization), gastro-intestinal, renal (serum creatinine \> 221 µmol/l (2.5 mg/dl) at randomization), pulmonary, endocrinologic or psychiatric disease. * Patients treated with oral amiodarone (more than 20 tablets during the 2 months preceding randomization) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.